Skip to main navigation Skip to search Skip to main content

Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations

  • James J. Harding
  • , Do Youn Oh
  • , Teresa Macarulla Mercade
  • , Lipika Goyal
  • , Andreas Varkaris
  • , Lola Jade Palmieri
  • , Masafumi Ikeda
  • , Shunsuke Kondo
  • , Li Yuan Bai
  • , Makoto Ueno
  • , Li Tzong Chen
  • , Kyriakos P. Papadopoulos
  • , Rachna T. Shroff
  • , Sani H. Kizilbash
  • , Antoine Hollebecque
  • , Jorge Adeva
  • , Rasha Cosman
  • , Tomoya Yokota
  • , Joon Oh Park
  • , Anita Turk
    • Chih Yi Liao, Taroh Satoh, Mitesh J. Borad, Anthony El-Khoueiry, Nilofer Azad, Kurt A. Jaeckle, Herbert H. Loong, Wei Peng Yong, Mark H. Bender, Sunoj Chacko Varughese, Deepa Sachdeva, David B. Radtke, Ivelina Gueorguieva, Anna M. Szpurka, Hsiao Rong Chen, Hui Liu, Xiaojian Xu, Jordi Rodon
  • Memorial Sloan-Kettering Cancer Center
  • Cornell University
  • Seoul National University
  • Vall d'Hebron Institute of Oncology
  • Massachusetts General Hospital Cancer Center
  • Stanford University
  • Centre Georges-François Leclerc
  • National Cancer Center Japan
  • Tokyo Women's Medical University
  • China Medical University Taichung
  • Kanagawa Cancer Center Research Institute
  • National Cheng Kung University
  • Kaohsiung Medical University
  • START Center for Cancer Care
  • University of Arizona
  • Mayo Clinic Rochester, MN
  • Gustave Roussy
  • Hospital Universitario 12 de Octubre
  • University of New South Wales
  • Shizuoka Cancer Center
  • Indiana University Bloomington
  • The University of Chicago
  • The University of Osaka
  • Mayo Clinic Scottsdale-Phoenix, Arizona
  • University of Southern California
  • Johns Hopkins University
  • Mayo Clinic in Jacksonville, Florida
  • Chinese University of Hong Kong
  • National University of Singapore
  • Eli Lilly
  • University of Texas MD Anderson Cancer Center

Research output: Contribution to journal › Article › peer-review

5   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science